Measure fatigue severity with the 9-item Fatigue Severity Scale. Assesses how fatigue affects motivation, exercise, physical functioning, work, and social life.
The Fatigue Severity Scale (FSS) is a 9-item self-report questionnaire that measures the severity of fatigue and its impact on daily functioning. Developed by Krupp et al. in 1989, the FSS was originally validated in multiple sclerosis (MS) and systemic lupus erythematosus (SLE). Each item is rated on a 1-7 Likert scale, and the mean score across all items is interpreted.
A mean FSS score of 4 or above indicates clinically significant fatigue. The FSS distinguishes fatigue from depression and sleepiness, has high test-retest reliability, and is sensitive to change with treatment interventions. It is one of the most widely used fatigue measures in neurology, rheumatology, and chronic disease research.
Fatigue is distinct from sleepiness — fatigue is a subjective sense of exhaustion that is not always relieved by sleep, while sleepiness (measured by the Epworth Sleepiness Scale) is the propensity to fall asleep. Many conditions, including MS, lupus, chronic fatigue syndrome, fibromyalgia, and post-COVID syndrome, feature fatigue as a primary disability driver.
Fatigue is the most common symptom reported in primary care and the most disabling symptom in many chronic diseases, yet it is rarely quantified objectively. The FSS provides a standardized, reproducible measure that facilitates communication between patients and providers, tracks treatment response, and supports disability documentation.
By separating fatigue into physical and functional domains, the FSS helps target interventions: physical reconditioning for exercise intolerance, occupational accommodations for work interference, and CBT for fatigue-related behavioral patterns.
FSS Mean = (Sum of all 9 item scores) / 9 Range: 1.0-7.0 <4.0: No significant fatigue (normal) 4.0-4.9: Mild fatigue 5.0-5.9: Moderate fatigue 6.0-7.0: Severe fatigue Clinical significance threshold: ≥4.0
Result: FSS Mean 4.5 — Mild Fatigue
A mean FSS of 4.5 exceeds the clinical significance threshold of 4.0, indicating mild but clinically meaningful fatigue. Sleep hygiene optimization, graded exercise therapy, and stress management are first-line recommendations.
Fatigue affects 75-90% of MS patients and is rated as the single most disabling symptom by nearly half of all patients, independent of physical disability level. MS-related fatigue is distinctive: worsened by heat (Uhthoff phenomenon), often present upon waking, and disproportionate to activity. The FSS was originally validated in MS and remains the most commonly used fatigue measure in MS clinical trials and care.
Long COVID (post-acute sequelae of SARS-CoV-2) features fatigue as the most common persistent symptom, reported in 50-70% of patients at 3-6 months. FSS scores in long COVID cohorts average 5.1, comparable to MS and SLE. The fatigue often includes post-exertional malaise, resembling ME/CFS. Graded exercise, pacing strategies, and rehabilitation programs show emerging benefit.
Fatigue (FSS), sleepiness (ESS), depression (PHQ-9), and deconditioning (functional capacity) are related but distinct constructs. A comprehensive assessment uses multiple validated tools to disentangle overlapping symptoms and target appropriate treatments for each contributing factor.
The FSS quantifies fatigue severity but does not identify the cause. Common causes include sleep disorders, anemia, thyroid disease, depression, chronic infection, autoimmune diseases, medications (beta-blockers, antihistamines, antidepressants), and neurological conditions (MS, Parkinson disease). A high FSS should prompt systematic evaluation.
While fatigue is common in depression, it also occurs independently. The FSS focuses on the functional impact of fatigue (exercise, physical tasks, work) rather than mood, anhedonia, or cognitive symptoms of depression. Depressed patients typically also score high on PHQ-9 or BDI-II, while patients with isolated fatigue (e.g., from MS) may have normal mood scales.
Yes. The FSS has been shown to be responsive to treatment effects in multiple clinical trials including immunomodulatory therapy for MS, CPAP for sleep apnea, thyroid hormone replacement, and exercise interventions. A change of ≥0.7 in the mean score is considered the minimal clinically important difference (MCID).
The standard FSS is validated for adults (≥18 years). Pediatric fatigue assessment tools include the PedsQL Multidimensional Fatigue Scale and the Pediatric Quality of Life Inventory fatigue module, which are more appropriate for children and adolescents.
CFS (also called myalgic encephalomyelitis/ME) is defined by persistent, debilitating fatigue lasting ≥6 months that is not explained by medical or psychiatric conditions and is accompanied by cognitive difficulties, post-exertional malaise, and unrefreshing sleep. FSS scores in CFS typically exceed 6.0.
Treatment depends on the underlying cause. General approaches include sleep optimization, graded exercise therapy, cognitive behavioral therapy for fatigue (CBT-F), energy conservation strategies, and treating identifiable causes (anemia, hypothyroidism, sleep apnea). Pharmacologic options include stimulants (modafinil, amantadine for MS) in select cases.